02 Jun Gentel Biosciences enters license agreement with German biotech
Madison, Wis. – Gentel Biosciences, a maker of protein microarrays, has signed a global license-and-supply agreement with Germany’s Eppendorf AG, enabling the Madison-based biotechnologhy company to access new markets in clinical research.
The agreement combines Gentel’s surface chemistry for protein assays with Eppendorf AG’s Silverquant, which is described as an ultra-sensitive analysis tool used for protein detection and quantification. Arrays are tests used by researchers to analyze the components of substances like proteins.
Alex Vodenlich, president and CEO of Gentel, said the agreement extends Gentel’s technology footprint beyond fluorescence-based microarray analysis. The company’s microarrays now are used in proteomics, the large-scale study of proteins, in discovery, medical care, and public safety.
Eppendorf, based in Hamburg, Germany, is a maker of research tools for the life science industry.
Related stories
• Gentel and Thermo Fisher advance new research tool
• Gentel launches cancer-fighting biomarker kit
• Gentel Biosciences hires VP of commercial operations